J9179 Injection, eribulin mesylate, 0.1 mg

Name of the Procedure:

Injection, Eribulin Mesylate, 0.1 mg
Common Names: Eribulin Injection, Halaven Injection
Technical Term: Injection, eribulin mesylate (HCPCS Code: J9179)

Summary

Eribulin mesylate is a type of chemotherapy drug used to treat certain types of cancer. Administered via an injection, it works by disrupting the growth and spread of cancer cells.

Purpose

Medical Conditions:
Primarily used for advanced or metastatic breast cancer and liposarcoma.

Goals/Outcomes:
To shrink tumors, slow down the progression of cancer, and alleviate cancer-related symptoms.

Indications

Symptoms/Conditions:

• Advanced or metastatic breast cancer after at least two prior chemotherapy regimens.
• Unresectable or metastatic liposarcoma.

Patient Criteria:

• Patients who have previously tried other chemotherapy treatments without success.

Preparation

• Attend a pre-procedure consultation with your oncologist.
• Blood tests may be required to check liver function and blood cell counts.
• No fasting is generally needed, but follow any specific instructions provided by your healthcare team.

Procedure Description

1. The patient checks into the infusion clinic or cancer treatment center.
2. A nurse or oncologist will prepare the eribulin mesylate injection.
3. The drug is administered intravenously over a short period through a vein.
4. The patient is monitored for any immediate reactions.

Tools/Equipment Used:

• IV line and infusion pump
• Pre-mixed eribulin mesylate solution

Anesthesia/Sedation:

• Not typically required, as it is a straightforward infusion process.

Duration

The injection itself takes about 2-5 minutes, but the entire visit, including monitoring, might take up to a few hours.

Setting

The procedure is usually performed in an outpatient setting such as:

• Hospital oncology units
• Specialized infusion centers
• Outpatient cancer treatment clinics

Personnel

• Oncology Nurse: Administers the injection and monitors the patient.
• Oncologist: Supervises the treatment and manages the overall treatment plan.

Risks and Complications

Common Risks:

• Nausea and vomiting
• Hair loss
• Fatigue

Rare Risks:

• Severe allergic reaction (anaphylaxis)
• Neutropenia (low white blood cell count), increasing infection risk
• Peripheral neuropathy (nerve damage)

Complications Management:
Most side effects can be managed with medications and supportive care.

Benefits

Expected Benefits:

• Tumor shrinkage
• Symptom relief
• Possible extension of survival time

Timeline for Benefits:

• Variable, depending on individual response to treatment.

Recovery

Post-Procedure Care:

• Rest and hydration are encouraged.
• Follow-up appointments to monitor blood counts and overall health.

Recovery Time:

• Most patients can resume normal activities shortly after the injection, though ongoing treatment cycles will continue on a doctor-recommended schedule.

Alternatives

Treatment Options:

• Other chemotherapy drugs (e.g., paclitaxel, anthracyclines)
• Hormonal therapy (for hormone receptor-positive cancers)
• Radiation therapy

Pros and Cons:

• Other chemotherapies may have different side-effect profiles and effectiveness.
• Hormonal therapies are less aggressive but only suitable for specific cancer types.
• Radiation can target localized tumors but isn't effective for widespread metastatic disease.

Patient Experience

During the Procedure:

• Mild discomfort from the IV insertion.

After the Procedure:

• Possible side effects like nausea or fatigue, which can be managed with medication.
• Supportive care may include antiemetics and rest.

Pain Management:

• Pain is generally minimal, managed by supportive medications for side effects.